BMY Bristol-Myers Squibb Company

62.93
+0.23  (0%)
Previous Close 62.70
Open 62.70
Price To book 7.02
Market Cap 103200571247
Shares 1,639,926,446
Volume 4,568,957
Short Ratio 1.87
Av. Daily Volume 6,455,188

SEC filingsSee all SEC filings

  1. 8-K - Current report 171083465
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 17985085
  3. 8-K - Current report 17984550
  4. 8-K - Current report 17965700
  5. 8-K - Current report 17910341

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial planned for 2017.
Opdivo and Rubraca
Castration-resistant prostate cancer (mCRPC)
Phase 3 trial planned for 2017.
Opdivo and Rubraca
Triple-negative breast cancers
Phase 3 trial planned for 2017.
Opdivo and Rubraca
Ovarian Cancer - First-line maintenance treatment
PDUFA date March 5, 2018 for sBLA filings across all approved indications.
Opdivo - 4 week applications
PDUFA date under priority review for sNDA of November 9, 2017.
Sprycel (dasatinib)
Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia
Phase 3 trial initiation announced July 10, 2017.
CABOMETYX (cabozantinib) with Opdivo and Yervoy - CheckMate 9ER
First-line renal cell carcinoma
Approval announced July 6, 2017.
ORENCIA
Psoriatic Arthritis (PsA)
Phase 1/2 preliminary data presented at ASCO June 2, 2017. ORR=21%.
CM-358 – Opdivo
Cervical, vaginal and vulvar cancers
Phase 1/2 ORR rate of 12.5% noted at ASCO June 3, 2017.
BMS-986016 - LAG-3 + Opdivo
Melanoma
Phase 3 trial initiated mid-2017.
ADCETRIS and Opdivo CM-812
Relapsed Hodgkin Lymphoma
PDUFA date under priority review September 24, 2017.
Opdivo (CM-040)
Previously Treated Hepatocellular Carcinoma
Phase 2 data due 2018.
TG4010 and Opdivo
Phase 2 late breaker at ASCO June 5, 2017. Control rate 44%. ORR 19%.
Opdivo + Yervoy
Malignant pleural mesothelioma (MPM)
Phase 1/2 initiated April 2017.
Epacadostat with Opdivo (nivolumab) - (ECHO-207)
Solid tumors
Phase 1/2 trial enrolling. Oral presentation at ASCO June 5, 2017.
Epacadostat with Opdivo (nivolumab) - (ECHO-204)
Solid tumors
Approval announced August 1, 2017.
CM-142 – Opdivo
(dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (CRC)
Phase 3 first overall survival (OS) positive data released April 3, 2017
CM - 067 Opdivo in combination with Yervoy
Melanoma
Phase 3 data released January 19, 2017.
Opdivo - ONO-4538-12
Gastric cancer
Phase 2 data due 2H 2018 – 1H 2019.
CM-568 - Opdivo + Yervoy
First-line Non-small cell lung cancer (NSCLC)
Phase 3 data due 1H 2018.
CM-651 – Opdivo + Yervoy
First-line Head and Neck Cancer
Phase 3 data due 2H 2018. Noted September 6, 2017 that trial has been placed on partial hold.
CM-602 – Opdivo + Elo + SOC
Myeloma
Phase 3 data due 2H 2017.
CM-459 – Opdivo
First-line Hepatocellular carcinoma (HCC) - cancer
Phase 3 data due 2H 2017.
CM-511 – Opdivo + Yervoy
First-line Melanoma
Phase 3 data due 1H 2018.
CM-451 – Opdivo + Yervoy
First-line Small cell lung cancer (SCLC)
Phase 3 data due 1H 2018.
CM-331– Opdivo
Second-line Small cell lung cancer (SCLC)
Phase 3 interim data released June 6, 2017 - primary endpoint met. Data presented at ESMO September 10, 2017 - HR 0.65 compared to Yervoy.
CM-238 – Opdivo (Adjuvant)
Melanoma
Phase 3 trial stopped early due to clear efficacy - trial met co-primary endpoint. HR 0.63.
CM-214 – Opdivo + Yervoy
First-line Renal cell carcinoma (RCC)
Phase 3 interim data due 4Q 2017. Primary completion 1Q 2018.
CM-227 – Opdivo + Yervoy
First-line Non-small cell lung cancer (NSCLC)
Phase 3 data released April 3, 2017 - primary endpoint not met.
CM-143 – Opdivo
Second-line Glioblastoma (GBM) cancer
Phase 3 data due 1H 2018.
CM-078 – Opdivo
Second-line Non-small cell lung cancer (NSCLC)
Phase 2 data due 1H 2018.
CM-548 - Opdivo+SOC
First-line Glioblastoma (GBM) cancer
Urothelial Carcinoma - Bladder cancer
Opdivo (nivolumab)
Bladder cancer

Latest News

  1. Buy Bristol-Myers Squibb Co (BMY) Stock With No Fear
  2. The Top Cancer Immunotherapies Expected to Reach $1 Billion in Sales in 2017
  3. Better Buy: Pfizer Inc. vs. Bristol-Myers Squibb
  4. Bristol-Myers Squibb Stock Still a Beast?
  5. Halozyme, Inovalon, and Teva Soared This Week: Can They Go Higher?
  6. Time to Adjust as Bristol-Myers Squibb Continues Its Climb
  7. Oncology Space in Focus this Week on ESMO Presentations
  8. Bristol-Myers (BMY) Collaborates With Halozyme for ENHANZE
  9. Pharma Stock Roundup: Achillion Slumps on End of HCV Deal, Teva Gets a New CEO
  10. Who Will Win the Kidney Cancer Battle Between Bristol-Myers Squibb and Exelixis?
  11. This Small Cap Biotech Soars On Deals With Bristol-Myers, Roche
  12. Halozyme to license drug delivery tech to Bristol-Myers a...
  13. Exelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale
  14. Here's Why Halozyme Therapeutics, Inc. Is Soaring Today
  15. Halozyme to license drug delivery tech to Roche, Bristol-Myers
  16. See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.
  17. Bristol To Pay Halozyme $105 Million To Make New Cancer Drugs Easier To Take
  18. Halozyme's stock soars after Bristol-Myers license deal
  19. Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers
  20. Bristol-Myers Squibb and Halozyme Enter Global Collaboration and License Agreement for ENHANZE Technology